Today let’s decode one of the most timely intersections in chronic illness right now. GLP-1 receptor agonists, the drug class behind Ozempic, Wegovy and Mounjaro, are being prescribed legitimately, and illegitimately, to millions of people worldwide. A significant proportion of those people have PoTS, dysautonomia or Long COVID. And the emerging eviden…
GLP-1 Medications and PoTS: Here Is What the Evidence Says.
Semaglutide improved one patient’s PoTS significantly. Tirzepatide made another dramatically worse. Both are GLP-1 receptor agonists. Here is why that actually makes biological sense.
